Special aspects of antiepileptic drug therapy in the elderly;Besonderheiten der Pharmakotherapie von Epilepsien im hoheren Lebensalter

Praxis

Volumn 86, Issue 37, 1997, Pages 1418-1423

  Kramer G ^a  

^a SWISS EPILEPSY CENTER   (Switzerland)

Author keywords

antiepileptic drugs; epilepsy in the elderly; pharmacotherapy

Indexed keywords

CARBAMAZEPINE; FELBAMATE; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; VALPROIC ACID; VIGABATRIN;

ADULT; AGED; BLOOD TOXICITY; DRUG ELIMINATION; DRUG INTOXICATION; DRUG METABOLISM; EPILEPSY; GAIT DISORDER; HUMAN; LIVER TOXICITY; REVIEW; TREMOR;

ADULT; AGED; ANTICONVULSANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; EPILEPSY; FEMALE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 0030767153     PISSN: 16618157     EISSN: 16618165     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Abernethy D.R., Azarnoff D.L.: Pharmacokinetic investigations in elderly patients. Clinical and ethical considerations. Clin. Pharmacokinet. 19, 89-93, 1990.
2. Bac, B., Hansen J.M., Kampmann J.P., Rasmussen S. N., Skovsted L. : Disposition of antipyrine and phenytoin correlated with age and liver volume in man. Clin. Pharmacokin. 6, 389-396, 1981.
3. Bauer L.A, Blouin R.A.: Age and phenytoin kinetics in adult epileptics. Clin. Pharmacol. Ther. 31, 301-304, 1982.
4. Bauer L.A., Davis R., Wilensky A., Raisys V., Levy R.H.: Valproic acid clearance: Unbound fraction and diurnal variation in young and elderly adults. Clin. Pharmacol. Ther. 37, 697-699, 1985.
5. Bay M.K.: The aging liver. In: Abrams, W.B., M.H. Beers, R. Berkow (eds.): The Merck Manual of Geriatrics, 2nd Edition. Merck & Co., Whitehouse Station, N.J., 696-699, 1995.
6. Beers MH, Ouslander J.G.: Risk factor in geriatric drug prescribing, A practical guide to avoiding problems. Drugs 37, 105-112, 1989.
7. Blaschke T.F., Cohen S.N., Tatro D.S., Rubin P. C.: Drug-drug, interactions and aging. In: Jarvik, L.F., D.J.Greenblatt, D.Harman (eds.). Clinical Pharmacology and the Aged Patient (Aging, Volume 16). Raven Press, New York, 11-26, 1981.
8. Boyd R.A., Bockbrader H.N., Türck D., Sedman A.J., Posvar E.L., Chang T.: Effect of subject age on the single dose pharmacokinetics of orally administered gabapentin (CI-945) (abstract). Pharm. Res. 7, Suppl. 9, S-215.
9. Bryson S.M., Verma N., Scott P.J.W., Rabin P.C.: Pharmacokinetics of valproic acid in young and elderly subjects. Br. J. Clin. Pharmacol. 16, 104-105, 1983.
10. Cameron H., Macphee G.J.A.: Anticonvulsant therapy in the elderly - A need for placebo controlled trials. Epilepsy Res. 21, 149-157, 1995.
11. Cloyd J.C., Lackner T.E., Leppik I.E.: Antiepileptic drugs in the elderly: pharmaco-epidemiology and pharmacokinetics. Arch. Family Med. 3, 589-598, 1994.
12. Craig I., Tallis R.: Impact of valproate and phenytoin on cognitive function in elderly patients: results of a single-blind randomized comparative study. Epilepsia 35, 381-390, 1994.
13. Cusack B.J., Vestal R.E.: Clinical Pharmacology. In: Abrams, W.B., M.H. Beers, R. Berkow (eds.): The Merck Manual of Geriatrics, 2nd Edition. Merck & Co., Whitehouse Station. N. J., 255-276, 1995.
14. Dawling S., Crome P.: Clinical pharmacokinetic considerations in the elderly. An update. Clin. Pharmacokinet. 17, 236-263, 1989.
15. Drinka P.J., Miller J., Voeks S.K., Hamel P.: Phenytoin binding in a nursing home geriatric patient population. J. Geriatr. Drug Ther. 3, 73-82, 1988.
16. Drury I., Beydoun A.: Seizure disorders of aging; differential diagnosis and patient management. Geriatrics, 48, 52-58, 1993.
17. Durnas C, Loi C.M., Cusack B.J.: Hepatic drug metabolism and aging. Clin. Pharmacokinet. 19, 359-389, 1990.
18. Eadie M.J., Lander C.M., Hooper W.D., Tyrer J.H.: Factors influencing plasma phenobarbitone levels in epileptic patients. Br. J. Clin. Pharmacol. 4, 541-547, 1977.
19. Fillastre J.P., Tubaret A.M., Fialaire A., Etienne I., Bidault R., Singlas E.: Pharmacokinetics of lamotrigine in patients with renal impairment: influence of hemodialysis. Drugs Exp. Clin. Res. 19, 25-32, 1993.
20. Furlanut M., Benetello P., Testa G., Da Ranch A.: The effects of dose, age, and sex on the serum levels of phenobarbital and diphenylhydantoin in epileptic patients. Pharmacol. Res. Comm. 10, 85-89, 1978.
21. Greenblatt D.J.: Reduced serum albumin concentration in the elderly: A report from the Boston collaborative drug surveillance program. J. Amer. Geriatr. Soc. 27, 20-22, 1979.
22. Greenblatt D.J., Shader R.I.: Pharmacokinetics in old age: Principles and problems of assessment. In: Jarvik, L.F., D.J.Greenblatt, D.Harman (eds.). Clinical Pharmacology and the Aged Patient (Aging, Vol. 16). Raven Press, New York, 27-46, 1981.
23. Greenblatt D.J., Abernethy D.R., Shader R.I.: Pharmacokinetic aspects of drug therapy in the elderly. Ther. Drug Monit. 8, 249-255, 1986.
24. Greenblatt D.J., Sellers E.M., Shader R.I.: Drug disposition in old age. New Engl. J. Med. 306, 1081-1089, 1982.
25. Haegele K.D., Huebert N.D., Ebel M., Tell G.P., Schechter PJ.: Pharmacokinetics of vigabatrin: Implications of creatinine clearance. Clin. Pharmacol. Ther. 44, 558-565, 1988.
26. Hasegawa H., Kanner A.M.: Seizure control after chronic pharmacotherapy in epileptic disorders beginning after 40 years of age. Clin. Neuropharmacol. 18, 13-22, 1995.
27. Hauser W. A.: Seizure disorders: the changes with age. Epilepsia 33, Suppl. 4, S6-S14, 1992.
28. Hayes M.J., Longman M.J.S., Short A.H.: Changes in drug metabolism with increasing age: 2. Phenytoin clearance and protein binding. Br. J. Clin. Pharmacol. 2, 73-79, 1975.
29. Hackings N., Pall A., Moody J., Davidson A.V.M., Davidson D.L. W.: The effects of age on carbamazepine pharmacokinetics and adverse effects. Br. J. Clin. Pharmacol. 22, 725-728, 1986.
30. Houghton G.W., Richens A., Leighton M.: Effect of age, height, weight and sex on serum phenytoin concentration in epileptic patients. Br. J. Clin. Pharmacol. 2, 251-256, 1975.
31. Jallon P., Loiseau P.: Epileptische Anfälle und Epilepsien beim älteren Menschen. SCIPP Vincennes / Sanofi-Winthrop, Münchenstein, 1995.
32. Lambie D.C., Caird F.I.: Phenytoin dosage in the elderly. Age and Aging 6, 133-137, 1977.
33. Lamy P.P.: The elderly and drug interactions. J. Amer. Geriatr. Soc 34, 586-592, 1986.
34. Lindeman R.D.: Changes in renal function with aging. Implications for treatment. Drugs & Aging 2, 423-431, 1992.
35. Mamoli B., Spatt J., Pankl W.: Zur Therapie der Altersepilepsie. Wien Klin. Wochenschr. 105, 453-458, 1993.
36. Martines C., Gatti G., Sasso E., Calzetti S., Perucca E.: The disposition of primidone in elderly patients. Br. J. Clin. Pharmacol. 30. 607-611, 1990.
37. Mattson R.H., Cramer J.A., Collins J.F., Smith D.B., Delgado-Escueta A.V., Browne T.R., Williamson P.D., Treiman D.M., McNamara J.O., McCutchen C.B, Homan R.W., Crill W.E., Lubozynski M.F., Rosenthat N.P., Mayersdorf A.: Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N. Engl. J. Med. 313, 145-151, 1985.
38. Mattson K.H., Cramer J.A., Collins J.F. and The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group: A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. N. Engl. J. Med. 327, 765-771, 1992.
39. Norris J.W., Hachinski V.C.: Mis-diagnosis of stroke. Lancet 1, 328-331, 1982.
40. Parker B.M., Vestal R.E.: Pharmacokinetics of anticonvulsant drugs in the elderly. In: Wyllie, E. (ed.). The Treatment of Epilepsy: Principles and Practice. Lea & Febiger, Philadelphia, 769-774, 1993.
41. Patterson M., Heazelwood R., Smithurst B., Eadie M.J.: Plasma protein binding of phenytoin in the aged: In vivo studies. Br. J. Clin. Pharmacol. 13, 423-425, 1982.
42. Pedersen B., Anderson C.: Treatment of epilepsy in old age. In: Chadwick, D. (ed.), Fourth International Symposium on Sodium Valproate and Epilepsy.Treatment of epilepsy in old age, Royal Society of Medicine Services Limited, London, New York, 130-132, 1989.
43. Perucca E., Grimaldi R., Gatti G., Pirracchio S., Crema F.. Frigo G.M.: Pharmacokinetics of valproic acid in the elderly. Br. J. Clin. Pharmacol. 17, 665-669, 1984.
44. Posner J., Holdich T., Crome P.: Comparison of lamotrigine pharmacokinetics in young and elderly healthy volunteers. J. Pharm. Med. 1, 121-128, 1991.
45. Reidenberg M.M., Odar-Cederlöf M.I., von Bahr C., Borgå O., Sjöqvist F.: Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function. New Engl. J. Med. 285, 264-267, 1971.
46. Rowan A.J., Ramsay R.E. (eds.): Seizures and Epilepsy in the Elderly. Butterworth-Heinemann, Boston, Oxford, 1997.
47. Rowe J. W.: Aging, renal function, and response to drugs. In: L. F. Jarvik, D.J.Greenblatt, D.Harman (eds.). Clinical Pharmacology and the Aged Patient (Aging, Vol. 16). Raven Press, New York, 115-130, 1981.
48. Scheuer M.L.: Seizures and epilepsy in the elderly. In: Pedley, T. A., Meldrum, B. S. (eds.). Recent Advances in Epilepsy, Number Six. Churchill Livingstone, Edinburgh, 247-270, 1995.
49. Scheuer M.L., Cohen J.: Seizures and epilepsy in the elderly. Neurol. Clinics 4, 787-804, 1993.
50. Schmidt D., Cornaggia D., Janz D.: Der Einfluss von Alter und Geschlecht auf die Plasmakonzentration von Phenytoin, Phenobarbital und Carbamazepin. In: O. Hallen, J. G. Meyer-Wahl, J. Braun (Hrsg.). Epilepsie 82. Spät- und Residual-Epilepsien Nebenwirkungen von Antikonvulsiva, Einhorn-Presse Verlag, Reinbek, 242-247, 1984.
51. Schumm F.: Altersepilepsie unter besonderer Berücksichtigung der Therapie. In: W. Fröscher (Hrsg.). Aspekte der Epilepsie-Therapie, Ueberreuter Wissenschaft, Wien, 27-36, 1989.
52. Tallis R.: Treatment of epilepsy in the elderly patient. In: S. Shorvon, F.Dreifuss, D.Fish, D. Thomas (eds.). The Treatment of Epilepsy, Blackwell Science, London, 227-237, 1996.
53. Tallis R., Easter D., Craig I.: Multicentre trial of valproate and phenytoin in elderly patients with newly diagnosed epilepsy (abstract). Age & Aging 23, Suppl. 2, P5, 1994.
54. Traeger A., Kiesewetter R., Kunze M.: Zur Pharmakokinetik von Phenobarbital bei Erwachsenen und Greisen. Dtsch. Ges.-wesen, 29, 1040-1042, 1974.
55. Treiman D.M., Meyers P.D., Walton N.Y.: Status epilepticus in the elderly: nosology and therapy. In: Rowan, A.J., Ramsay, R.E. (eds.): Seizures and Epilepsy in the Elderly. Butterworth-Heinemann, Boston, Oxford, 207-215, 1997.
56. Troupin A.S., Johannessen S.I.: Epilepsy in the elderly. A pharmacologic perspective. In: D. B. Smith (ed.). Epilepsy: Current Approaches to Diagnosis and Treatment, Raven Press, New York. 141-143, 1990.
57. van Heiningen P.N.M., Eve M.D., Oosterhuis B., Jonkman J.H.G., de Bruin H., Hulsman J.A.R.J., Richens A., Klosterskov Jensen P.: The influence of age on the pharmacokinetics of the antiepileptic agent oxcarbazepine. Clin. Pharmacol. Ther. 50, 410-419, 1991.
58. Verbeeck R.K., Cardinal J.A., Wallace S.M.: Effect of age and sex on the plasma binding of acidic and basic drugs. Eur. J. Clin. Pharmacol. 27, 91-97, 1984.
59. Willmore L.J.: The effect of age on pharmacokinetics of antiepileptic drugs. Epilepsia 36, 14-21, 1995.
60. Willmore L.J., Dulac O.: Use of antiepileptic drugs in children and the elderly (general principles). In: Levy R.H., Mattson R.H., Meldrum B.S. (eds.). Antiepileptic Drugs, fourth edition. Raven Press, New York, 231-242, 1995.